Latest filing published 16 Apr 2018 for Oncotelic Therapeutics, Inc..
Insider track record
No signal scores available.
Closed purchases
Not enough history yet: 1 closed purchase, at least 2 are needed.
Purchases by company
Since each purchase
- +18.4%Entry 0.76 · Close at T+365 0.90
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Matthew M. Loar: trading record in brief
Filings by Matthew M. Loar span 2 companies, the busiest being Neurobiological Technologies Inc /CA/ and Oncotelic Therapeutics, Inc. The record holds 2 filings, for trades running from 22 October 2008 to 12 April 2018.
On the market, this insider has only ever bought: 2 purchases, €14k in total. No amount is published for 1 filing, which the totals therefore leave out. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. In 2018 alone, the filings show 1 purchase and no sales.
The latest filing, published on 16 April 2018, reports an open-market purchase in Oncotelic Therapeutics, Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Matthew M. Loar
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 250,000 sharesCommon StockSEC:0001209191-18-024986:0Canonical exit: 11 Jul 2018 (T+90)
- 25,000 shares@ US$0.75Common StockSEC:0001181431-08-058080:0Canonical exit: 20 Jan 2009 (T+90)
2 of 2 declarations
